NCT00398073View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Intraocular MelanomaMelanoma (Skin)
Interventions
BIOLOGICAL

mouse gp100 plasmid DNA vaccine

DEVICE

The Dermal PowderMed® devices

OTHER

intramuscularly (IM injection)

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00398073 - Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | Biotech Hunter | Biotech Hunter